hOS's $12.8M Seed Round Backs a Stealth Bet on AI for Human Prosperity

DataRobot founder Jeremy Achin leads the stealth startup, which has secured funding from NEA and Sequoia but remains tight-lipped on its specific clinical or commercial target.

About hOS

Published

The most ambitious AI companies often start with a problem, not a product. For hOS, a startup operating in near-total stealth since its 2021 founding, the problem is framed in starkly human terms: to maximize prosperity and minimize suffering [Home | hOS, retrieved 2024]. The company, founded by DataRobot’s former CEO Jeremy Achin and a cadre of his former colleagues, has secured a significant $12,800,000 seed round from a consortium of top-tier investors led by NEA [PR Newswire, February 2022].

The DataRobot pedigree as a strategic asset

The primary signal for investors, in the absence of public product details, is the team. Jeremy Achin built DataRobot into an enterprise AI platform once valued at nearly $3 billion [The Information, retrieved 2026]. He is joined by co-founder Natalie Hogan, DataRobot’s former Chief Administrative Officer, and several other alumni [Home | hOS, retrieved 2024].

Founder Role at hOS Key Prior Experience
Jeremy Achin CEO, Co-founder Founder & CEO, DataRobot
Natalie Hogan COO, Co-founder Chief Administrative Officer, DataRobot
Andrey Oleksiuk CTO, Co-founder Not specified in sources
Nate McKenzie Co-founder Founder experience, DataRobot alumni [RocketReach, retrieved 2026]
Nick Bundzinski Co-founder Not specified in sources

The strategic silence and its implications

Operating in stealth for this long, with this level of funding, is a deliberate strategy. Public statements are limited to the broad ambition of developing "AI-driven technologies for humans" and seeking "early users to participate and provide feedback" [Home | hOS, retrieved 2024] [Nate McKenzie - Innovative Entrepreneur | Startup Builder, retrieved 2026].

The path from stealth to standard of care

The ultimate test for hOS will be its transition from a well-funded experiment to a tool that changes outcomes for a defined group of people. The next twelve months will be critical. Observers should watch for signs of a first clinical or commercial partnership, a regulatory filing, or a targeted hiring surge in a specific domain.

Read on Startuply.vc